Soursop (Graviola)

Tropical fruit: Complex-I/ROS ↑/↓, EMT ↓; preclinical in breast/prostate/lung/colorectal; neurotoxicity caution.

AI extractedhuman reviewedsources checkedretractions suppressed

🔬⭐⭐ Preclinical — Compelling mechanisms but no therapeutic human trials; safety concerns at high exposure.Annona muricataGuanabanaGraviola leaf/fruit extract

Forms: Leaf/fruit extract capsules (500-1000 mg standardized acetogenins) · Tea (dried leaves, 1-2 g/day)

Educational only, not medical advice. OncoForge makes no claim that Soursop (Graviola) treats, prevents, or cures any condition, beyond what the linked studies show. Evidence levels vary; effects may not translate to people, and some compounds can cause harm. Always coordinate with your oncology team.

Key Takeaway

Acetogenins inhibit mitochondrial Complex I, elevate ROS, and can downshift EMT/invasion—yielding selective cytotoxicity in models. Human therapeutic data are lacking, and high exposure has neurotoxicity signals; treat as experimental.

Evidence at a glance

Tier 1 · labBreastProstateLungColorectal

Preclinical Complex I/ROS/EMT robust; no oncology trials; epi-neurotoxicity signals strong; ongoing safety/PK in natural products.

How it may work

Annona acetogenins (e.g., annonacin) bind NADH dehydrogenase (Complex I), collapsing mitochondrial ATP production and increasing ROS → caspase activation and apoptosis/necrosis. Parallel suppression of PI3K/Akt/NF-κB and EMT transcription factors (Snail/ZEB1) reduces migration and invasion. Combination studies suggest additivity with platinums and polyphenols via oxidative and metabolic stress.

Targets & pathways

Curated mechanistic targets reported for this agent — how it may act on cells, not proof of a clinical effect.

Complex-I↓NADH dehydrogenase inhibition
ROS↑Mitochondrial superoxide elevation
EMT↓Snail/ZEB1 suppression
Apoptosis↑Caspase activation
PI3K/Akt/NF-κB↓Survival signaling inhibition

Complex-IROSEMT

Often studied / combined with

Combinations reported in the literature, not a protocol or a recommendation.

Cisplatin: ROS and response in lung cancer models.
Curcumin: Apoptosis boost in colorectal xenografts.
Resveratrol: EMT co-inhibition in breast cancer.

Overlapping mechanisms

ROS ↑: Overlaps pro-oxidants; oxidative overload risk.
Complex-I ↓: Redundant with metformin; monitor ATP.

Safety & interactions

Severity and how well-established each signal is are shown separately. Verify everything with your oncologist or pharmacist — absence here does not mean safe.

Risk categories

NeurotoxicityGi UpsetPregnancy Avoid

Potential interactions

neurotoxic_chemoCautionModerateTheoreticalAdditive neuropathy (e.g., taxanes).
antioxidantsMonitorLowTheoreticalMay blunt ROS mechanism.
CisplatinSynergizeLowTheoreticalROS enhancement in lung models.

Timing

With-meal: Reduces GI irritation.
BID: Short cycles (1-2 weeks).

References

Research

No published studies for Soursop (Graviola) yet

New studies appear here once they’ve been reviewed. Browse all studies.

Dose: as studied, not a recommendation

These are doses as studied or reported, never a recommendation. The right amount of Soursop (Graviola) depends on you, your other medicines, and your situation; decide it with your oncology team and pharmacist, not from a web page.

Ranges seen in adjunct / practice use: 500–1500 mg/day (po) divided BID; short-term research use, Preclinical 10-50 mg/kg; human extrapolated 500-1000 mg/day extract; avoid chronic >2 weeks due to neurotoxicity; monitor neuro symptoms..

Trials studying Soursop (Graviola)

No actively-recruiting trials matched right now. Recruiting is not the same as proven. Search ClinicalTrials.gov →

Inclusion here is not an endorsement. OncoForge makes no claim beyond what the linked studies show. Discuss anything on this page with your oncology team before acting on it.

← All agents · Research Radar